Cell:蛋白TTP抑制Myc引发的淋巴瘤

2012-08-09 T.Shen 生物谷

近日,来自斯克利普斯研究所的科学家发现了一种蛋白质可以破坏淋巴瘤(一种淋巴结癌)的生长和维持机能,但是这种蛋白质在疾病的早期阶段是被抑制的。相关研究刊登在8月3日的国际杂志Cell上。这项研究重点关注了新的肿瘤抑制子在Myc肿瘤基因蛋白诱导下的淋巴瘤中扮演的角色,研究者指出这种调节循环回路在所有MYC参与的人类肿瘤中都发生。 Myc家族癌基因蛋白Myc包括C-、N-和L-Myc,其可以调节影响肿

近日,来自斯克利普斯研究所的科学家发现了一种蛋白质可以破坏淋巴瘤(一种淋巴结癌)的生长和维持机能,但是这种蛋白质在疾病的早期阶段是被抑制的。相关研究刊登在8月3日的国际杂志Cell上。这项研究重点关注了新的肿瘤抑制子在Myc肿瘤基因蛋白诱导下的淋巴瘤中扮演的角色,研究者指出这种调节循环回路在所有MYC参与的人类肿瘤中都发生。

Myc家族癌基因蛋白Myc包括C-、N-和L-Myc,其可以调节影响肿瘤的关键途径,C-Myc的表达在人类伯基特淋巴瘤中是被激活的,对于诱导足够的肿瘤生长是必须的。

这项研究中,研究者研究了癌变前和恶性的Myc表达 B细胞(人类淋巴瘤中部分受影响的免疫系统),使用转基因动物模型,研究者揭示了Myc直接抑制蛋白tristetraprolin(TTP/ZFP36)对于癌症的发展和维持至关重要,抑制TTP是MYC介导的癌症的一个标志。

科学家的结果揭示了在Myc引发的淋巴瘤中再引入TTP可以使得肿瘤失活,这成为一种新的治疗靶点。Myc可以调节成千上万个基因,包括腺苷酸-尿苷酸丰富的元件(AU-丰富元件),AU-丰富元件在维持RNA稳定性上比较重要,可以知道mRNA降解,也可以控制细胞生长过程中控制基因表达。

“Myc调节选择性的AU结合蛋白表达,随后来控制特定mRNAs的破坏,而且我们的研究也揭示了其它的AU结合蛋白可以作为肿瘤抑制子抑制其它肿瘤”,研究者Cleveland这样说,这项研究由美国国家健康中心支持。

编译自:Critical Tumor Suppressor for Cancer Identified

doi:10.1016/j.cell.2012.06.033
PMC:
PMID:

Tristetraprolin Impairs Myc-Induced Lymphoma and Abolishes the Malignant State

Robert J. Rounbehler, Mohammad Fallahi, Chunying Yang, Meredith A. Steeves, Weimin Li, Joanne R. Doherty, Franz X. Schaub, Sandhya Sanduja, Dan A. Dixon, Perry J. Blackshear, John L. Cleveland

Myc oncoproteins directly regulate transcription by binding to target genes, yet this only explains a fraction of the genes affected by Myc. mRNA turnover is controlled via AU-binding proteins (AUBPs) that recognize AU-rich elements (AREs) found within many transcripts. Analyses of precancerous and malignant Myc-expressing B cells revealed that Myc regulates hundreds of ARE-containing (ARED) genes and select AUBPs. Notably, Myc directly suppresses transcription of Tristetraprolin (TTP/ZFP36), an mRNA-destabilizing AUBP, and this circuit is also operational during B lymphopoiesis and IL7 signaling. Importantly, TTP suppression is a hallmark of cancers with MYC involvement, and restoring TTP impairs Myc-induced lymphomagenesis and abolishes maintenance of the malignant state. Further, there is a selection for TTP loss in malignancy; thus, TTP functions as a tumor suppressor. Finally, Myc/TTP-directed control of select cancer-associated ARED genes is disabled during lymphomagenesis. Thus, Myc targets AUBPs to regulate ARED genes that control tumorigenesis.

(责任编辑:shentuo)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1958811, encodeId=89d01958811e7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 13 08:09:00 CST 2012, time=2012-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005354, encodeId=0cf9200535464, content=<a href='/topic/show?id=e8fb1e9130f' target=_blank style='color:#2F92EE;'>#TTP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17913, encryptionId=e8fb1e9130f, topicName=TTP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Sat Apr 13 10:09:00 CST 2013, time=2013-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868578, encodeId=66df18685e853, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Nov 06 02:09:00 CST 2012, time=2012-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274781, encodeId=a90712e4781b5, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Aug 11 02:09:00 CST 2012, time=2012-08-11, status=1, ipAttribution=)]
    2012-11-13 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1958811, encodeId=89d01958811e7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 13 08:09:00 CST 2012, time=2012-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005354, encodeId=0cf9200535464, content=<a href='/topic/show?id=e8fb1e9130f' target=_blank style='color:#2F92EE;'>#TTP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17913, encryptionId=e8fb1e9130f, topicName=TTP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Sat Apr 13 10:09:00 CST 2013, time=2013-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868578, encodeId=66df18685e853, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Nov 06 02:09:00 CST 2012, time=2012-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274781, encodeId=a90712e4781b5, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Aug 11 02:09:00 CST 2012, time=2012-08-11, status=1, ipAttribution=)]
    2013-04-13 lilili1104
  3. [GetPortalCommentsPageByObjectIdResponse(id=1958811, encodeId=89d01958811e7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 13 08:09:00 CST 2012, time=2012-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005354, encodeId=0cf9200535464, content=<a href='/topic/show?id=e8fb1e9130f' target=_blank style='color:#2F92EE;'>#TTP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17913, encryptionId=e8fb1e9130f, topicName=TTP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Sat Apr 13 10:09:00 CST 2013, time=2013-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868578, encodeId=66df18685e853, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Nov 06 02:09:00 CST 2012, time=2012-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274781, encodeId=a90712e4781b5, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Aug 11 02:09:00 CST 2012, time=2012-08-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1958811, encodeId=89d01958811e7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 13 08:09:00 CST 2012, time=2012-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005354, encodeId=0cf9200535464, content=<a href='/topic/show?id=e8fb1e9130f' target=_blank style='color:#2F92EE;'>#TTP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17913, encryptionId=e8fb1e9130f, topicName=TTP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Sat Apr 13 10:09:00 CST 2013, time=2013-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868578, encodeId=66df18685e853, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Nov 06 02:09:00 CST 2012, time=2012-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274781, encodeId=a90712e4781b5, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Aug 11 02:09:00 CST 2012, time=2012-08-11, status=1, ipAttribution=)]
    2012-08-11 仁者大医